Table 2.

Multivariate survival analysis comparing recent types of anti-cancer treatment in patients with cancer and COVID-19, adjusted for age and co-morbidities (hypertension and cerebrovascular disease).

	HR (95% CI)	p-value
All systemic anti-cancer therapy	2.30 (1.16–4.6)	0.02
All chemotherapy	2.04 (0.84–4.9)	0.11
Palliative chemotherapy	2.29 (0.87–6.0)	0.09
Neoadjuvant/adjuvant chemotherapy	1.32 (0.30–5.9)	0.71
Endocrine therapy	1.94 (0.74–5.1)	0.18
Targeted anti-cancer therapy	3.44 (0.44–27.2)	0.24
Immunotherapy	1.70 (0.39–7.3)	0.48
Radiotherapy	1.94 (0.45–8.4)	0.38
Surgery	1.40 (0.18–10.8)	0.75